Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $143.34 billion. The enterprise value is $190.29 billion.
Important Dates
The next confirmed earnings date is Tuesday, February 3, 2026, before market open.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Jan 23, 2026 |
Share Statistics
Pfizer has 5.69 billion shares outstanding. The number of shares has increased by 0.18% in one year.
| Current Share Class | 5.69B |
| Shares Outstanding | 5.69B |
| Shares Change (YoY) | +0.18% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 66.43% |
| Float | 5.68B |
Valuation Ratios
The trailing PE ratio is 14.60 and the forward PE ratio is 8.60.
| PE Ratio | 14.60 |
| Forward PE | 8.60 |
| PS Ratio | 2.28 |
| Forward PS | 2.29 |
| PB Ratio | 1.54 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 13.81 |
| P/OCF Ratio | 10.96 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.78, with an EV/FCF ratio of 18.34.
| EV / Earnings | 19.36 |
| EV / Sales | 3.03 |
| EV / EBITDA | 7.78 |
| EV / EBIT | 10.70 |
| EV / FCF | 18.34 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.28 |
| Quick Ratio | 0.90 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 2.42 |
| Debt / FCF | 5.97 |
| Interest Coverage | 6.59 |
Financial Efficiency
Return on equity (ROE) is 10.60% and return on invested capital (ROIC) is 7.04%.
| Return on Equity (ROE) | 10.60% |
| Return on Assets (ROA) | 5.19% |
| Return on Invested Capital (ROIC) | 7.04% |
| Return on Capital Employed (ROCE) | 10.33% |
| Revenue Per Employee | $775,123 |
| Profits Per Employee | $121,346 |
| Employee Count | 81,000 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.36 |
Taxes
| Income Tax | -685.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.36% in the last 52 weeks. The beta is 0.42, so Pfizer's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -4.36% |
| 50-Day Moving Average | 25.08 |
| 200-Day Moving Average | 24.51 |
| Relative Strength Index (RSI) | 47.78 |
| Average Volume (20 Days) | 50,908,204 |
Short Selling Information
The latest short interest is 139.07 million, so 2.45% of the outstanding shares have been sold short.
| Short Interest | 139.07M |
| Short Previous Month | 126.59M |
| Short % of Shares Out | 2.45% |
| Short % of Float | 2.45% |
| Short Ratio (days to cover) | 1.48 |
Income Statement
In the last 12 months, Pfizer had revenue of $62.79 billion and earned $9.83 billion in profits. Earnings per share was $1.73.
| Revenue | 62.79B |
| Gross Profit | 46.97B |
| Operating Income | 17.78B |
| Pretax Income | 9.15B |
| Net Income | 9.83B |
| EBITDA | 24.46B |
| EBIT | 17.78B |
| Earnings Per Share (EPS) | $1.73 |
Full Income StatementBalance Sheet
The company has $14.99 billion in cash and $61.94 billion in debt, giving a net cash position of -$46.95 billion or -$8.26 per share.
| Cash & Cash Equivalents | 14.99B |
| Total Debt | 61.94B |
| Net Cash | -46.95B |
| Net Cash Per Share | -$8.26 |
| Equity (Book Value) | 93.10B |
| Book Value Per Share | 16.32 |
| Working Capital | 10.33B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $13.08 billion and capital expenditures -$2.70 billion, giving a free cash flow of $10.38 billion.
| Operating Cash Flow | 13.08B |
| Capital Expenditures | -2.70B |
| Free Cash Flow | 10.38B |
| FCF Per Share | $1.82 |
Full Cash Flow StatementMargins
Gross margin is 74.81%, with operating and profit margins of 28.31% and 15.66%.
| Gross Margin | 74.81% |
| Operating Margin | 28.31% |
| Pretax Margin | 14.58% |
| Profit Margin | 15.66% |
| EBITDA Margin | 38.96% |
| EBIT Margin | 28.31% |
| FCF Margin | 16.53% |
Dividends & Yields
This stock pays an annual dividend of $1.72, which amounts to a dividend yield of 6.82%.
| Dividend Per Share | $1.72 |
| Dividend Yield | 6.82% |
| Dividend Growth (YoY) | 1.78% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 99.64% |
| Buyback Yield | -0.18% |
| Shareholder Yield | 6.64% |
| Earnings Yield | 6.86% |
| FCF Yield | 7.24% |
Dividend DetailsAnalyst Forecast
The average price target for Pfizer is $27.40, which is 8.69% higher than the current price. The consensus rating is "Hold".
| Price Target | $27.40 |
| Price Target Difference | 8.69% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | -2.41% |
| EPS Growth Forecast (5Y) | 9.52% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 1, 1999. It was a forward split with a ratio of 3:1.
| Last Split Date | Jul 1, 1999 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Pfizer has an Altman Z-Score of 2.2 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.2 |
| Piotroski F-Score | 7 |
